Aureka Biotechnologies Raises $100M Series B, Total Funding Nears $200M

For founders and investors, Aureka's rapid $100M Series B—just a year or two after its initial rounds—demonstrates the breakneck pace at which AI-driven biotech startups can scale. The dual-tranche structure, with an exclusive first tranche from Granite Asia and a later strategic lead, suggests strong inside confidence and a likely partnership or M&A path. With nearly $200M total funding in three years, Aureka is now in a high-stakes race to deliver clinical validation and justify an inevitably soaring valuation.

Aureka Biotechnologies, a 2023-founded AI-native TechBio company, announced the close of a US$100 million Series B financing on August 10, 2026, bringing its total funding to nearly US$200 million. The round was structured in two tranches: an initial exclusive investment by Granite Asia, followed by a second tranche led by an unnamed prominent strategic investor, with participation from HighLight Capital (HLC) and existing backers MPCi and NRL Capital. This capital injection marks a significant milestone not just for the company but for the broader AI-driven drug discovery sector, as it underscores investor confidence in the pivot from using AI merely as a tool for efficiency toward building comprehensive biological world models that can fundamentally understand, generate, and predict complex living systems.

“

Aureka Biotechnologies, a 2023-founded AI-native TechBio company, announced the close of a US$100 million Series B financing on August 10, 2026, bringing its total funding to nearly US$200 million.

The proceeds are earmarked primarily for research and large-scale training of next-generation biological foundation models. These models aim to excel at de novo molecular design, biological structure modeling, and function prediction—core tasks that have historically required laborious trial-and-error. Aureka also plans to upgrade its ‘Lab-in-the-Loop’ experiment-centered feedback engine, which integrates single-cell functional screening, high-throughput experimental validation, and drug development platforms. This creates a tightly coupled loop where AI models propose hypotheses and learn from real-world experimental results, potentially accelerating the drug discovery cycle from years to months. The company’s infrastructure already combines large-scale pre-training, project-specific post-training, AI agents, and automated experiments into what it calls an ‘AI-for-Science’ stack—a phrase that captures the ambition to make models that do not just solve individual tasks but internalize the rules of biology.

The market context is critical: the pharmaceutical industry is grappling with Eroom’s Law, where the cost of developing a new drug doubles roughly every nine years. AI-native biotechs have been attracting massive funding rounds in hopes of breaking that curve. Aureka’s focus on a closed-loop system where dry-lab AI and wet-lab experimentation feed each other positions it alongside emerging players like Recursion, Insilico Medicine, and Generate Biomedicines—though Aureka’s emphasis on building a generalizable world model rather than a pipeline of individual drug candidates marks a philosophical divergence. If successful, such a model could be licensed across multiple therapeutic areas, creating a platform business with potentially exponential returns.